Advanced Cell Models – Webinars and Online Events

Bio-Techne has extensive experience in and offers a strong and diverse portfolio for the generation, maintenance and characterization of organoids and other 3D culture systems such as spheroids.

This exclusive on-demand AMA event grants you unprecedented access to the pioneering expert Prof. Donald Ingber, delving deep into the captivating realm of body-on-a-chip technology– completely free of charge.

Enhance your research by gaining a solid understanding of how to unravel tissue complexity and how to establish an optimized workflow for 3D imaging in your lab.

Traditional organoid culture can present challenges for the downstream analysis of single organoids. In this webinar, Dr. Allysa Stern will discuss a unique workflow that enables clonal organoid development, monitoring of iPSC differentiation over time and automated isolation of single organoids.

Dr. Scott Magness will then present a case related to his group’s work investigating tumor cell heterogeneity through clonal organoid morphology and transcriptomics. He will discuss new approaches using single organoid transcriptomics to evaluate organoids derived from single cells from gastric dysplastic tissues and how this approach might reveal new ways to investigate tumor cell heterogeneity and evasion of some cells from cancer treatments.

In this webinar series, speakers describe the development of an in-house 3D drug sensitivity and resistance testing platform, the development of a pipeline to functionally evaluate 3D organoid models from patients with genitourinary tumors, and how to better understand your 3D cell models and make insightful discoveries.

Join the webinar to learn how:

• Liver disease progresses from a dysregulation of metabolism
• Lipid metabolism differs between mice and men and the impact this has on drug development
• Primary human NASH models can evaluate drugs that target metabolism
• NASH models allow the quantitation of lipid droplets, metabolism and fibrosis

In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.

Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.

Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?

In this webinar, Dr. Holz will discuss the background of cell-to-cell communication, highlighting studies and recent developments in the field as well as exploring the clinical implications of these studies on cancer biology and patient care.

The administration of drugs via inhalation into the lungs is superior to many other methods of delivery because our lungs provide a large surface area for absorption, access to the whole blood volume and comparatively little metabolic activity. Currently, there are limited in vitro models in which the absorption and permeability of drugs across the lung and into systemic circulation can be precisely measured.

In this webinar, Dr. Emily Richardson will describe novel lung-on-a-chip (LOAC), otherwise known as lung microphysiolological system, models of the alveoli and bronchi which can be used to accurately predict drug pharmacokinetics, allowing for more rapid, precise and cost-effective analysis of compounds.